DM; BML-275; Compound C; AMPK Inhibitor
Dorsomorphin is a cell-permeable, potent, selective, reversible and ATP-conmpetitive inhibitor of adenosine monophosphate protein kinase (AMPK) (Ki=109 nM in the presence of ATP and no AMP). It does not display significant inhibition of JAK3, PKA, PKCθ, SYK and ZAPK.
The selective compound suppresses fatty acid synthase and food intake in mice. By being competitive with ATP to AMPK, it downregulates the expression of SREBP-1, which is a lipogenic transcription factor, and have hepatocytes produce glucose.
Dorsomorphin also dose-dependently inhibits bone morphogenic protein type I of receptors (BMPR), such as ALK2, ALK3 and ALK6). BMP is required for iron metabolism and embryogenesis.
In pluripotent embryonic stem (ES) cells of mice, this compound has been reported to induce cardiomyogenesis robustly. In addition, it also promotes significant neural differentiation in human pluripotent stem cells (hPSC).
- Inhibitor of adenosine monophosphate-activated (AMP) protein kinase (AMPK)
- Inhibitor of bone morphogenetic protein (BMP) receptors (BMPR)
- Inhibitor of fatty acid synthase
- Inhibitor of ACTR-1
- Inducer of autophagy
Research or further manufacturing use only, not for food or drug use.